This is a prospective clinical trial (a study where individuals are followed over time) examining the immune response of participants receiving Modified Vaccinia Ankara (MVA), a vaccine for the prevention of monkeypox (Mpox) infection. Participants may receive MVA 0.1ml intradermally (a shallow injection) or MVA 0.5ml subcutaneously (a deeper injection) on one or two occasions as part of routine clinical care. Participants will attend 5 follow up visits over 48 weeks after their first dose of MVA. The main aim of this trial is to find out the rate of change of (durability), and factors associated with, MVA-specific antibodies (proteins that help remove infection) after 48 weeks post vaccination with MVA.
| Study Type: | Clinical Trial |
| Clinical Area: | Infectious Diseases |
| Condition: | MPOX |
| Principal Investigator: | Prof Mary Horgan |
| Study Coordinator: | Ciara McHugh |
| Key Eligibility Criteria: | ≥ 18 years old, Eligible for 1 or 2 doses of MVA for Mpox prevention as per NIAC guidelines |
| Contact email: | ciaramchugh@mater.ie |